{"analyses":[{"ciLowerLimit":"0.66","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.06","groupDescription":"Stratified by: stage and/or surgical status (Stage III vs. Stage IV), ECOG performance status (0 vs. 1 or 2) and treatment strategy (adjuvant vs. neoadjuvant).","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.1316","paramType":"Hazard Ratio (HR)","paramValue":"0.83","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of 95% CI was not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG000","lowerLimit":"45.54","upperLimit":"NA","value":"49.15"},{"comment":"67.3% of the participants were censored and the median was not reached.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"393"},{"groupId":"OG001","value":"391"}],"units":"Participants"}],"description":"Overall Survival (OS) is defined as the time from randomization to death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.","id":"OG000","title":"Placebo With Paclitaxel, Carboplatin and Bevacizumab"},{"description":"Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.","id":"OG001","title":"Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab"}],"paramType":"MEDIAN","populationDescription":"PD-L1-positive subpopulation is defined as patients in the ITT population whose PD-L1 status was IC1/2/3 at the time of randomization.","reportingStatus":"POSTED","timeFrame":"From randomization up to death from any cause (up to approximately 59 months)","title":"Overall Survival - PD-L1-Positive Subpopulation","type":"PRIMARY","unitOfMeasure":"Months"}